C-EHYLMogrify
direct cellular reprogramming, epigenetics, transcription factors
reprogrammingepigenetic reprogramming
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EHYL
C-EHYLC-EHYLdirect cellular reprogramming, epigenetics, transcription factors
0-100 chain-logic scale · 15 dimensions · scored on public evidence
mogrify/LICENSE.md at master · elixir-mogrify/mogrify · GitHub Skip to content Navigation Menu Toggle navigation Sign in Appearance settings Platform AI CODE CREATION GitHub Copilot Write better code with AI GitHub Copilot app Direct agents from issue to merge MCP Registry New Integrate external tools DEVELOPER WORKFLOWS Actions Automate any workflow Codespaces Instant dev environments Issues Plan and track work Code Review Manage code changes APPLICATION SECURITY GitHub Advanced Security Find and fix vulnerabilities Code security Secure your code as you build Secret protection Stop leaks befo … Trust center Partners View all resources Open Source COMMUNITY GitHub Sponsors Fund open source developers PROGRAMS Security Lab Maintainer Community Accelerator GitHub Stars Archive Program REPOSITORIES Topics Trending Collections Enterprise ENTERPRISE SOLUTIONS Enterprise platform AI-powered developer platform AVAILABLE ADD-ONS GitHub Advanced Security Enterprise-grade security features Copilot for Business Enterprise-grade AI features Premium Support Enterprise-grade 24/7 … our input very seriously. Include my email address so I can be contacted Cancel Submit feedback Saved searches Use saved searches to filter your results more quickly --> Name Query To see all available qualifiers, see our documentation . Cancel Create saved search Sign in Sign up Appearance settings Resetting focus You signed in with another tab or window. Reload to refresh your session. You signed out in another tab or window. Reload to refresh your session. You switched acc
%PDF-1.5 %���� 2 0 obj > endobj 7 0 obj > stream x��T�r�0}�Wh�#ȒoI���) ��S���")����Q���x����NB�R.y��ڳgW{9��fU��ڭKkr #m�U�����%a���(QY�sl,>/��M-��h�oK����;F����t�f�Dߕo ����a. �e�Z��7�z��@Ӭy�c��Bs8�����s|�З�5�X�Q$D26@#�i6��W(bဲ���b ����ᇋ3� ;��7��C8����5�t���8�Y�Q�("� ��!f�bOr��te��L>%��WudJR]�6~M� l_�a�^l��gҮ(��� �� *� A>�8 �� � �rӎ�մ�lJ�aGC�b�aH�i��"�1���, .#9��8����ʴK+��7I��4�Y�"� %Ydz@� ��( %����������د�5���r�ۡ0 ��'�S���{m��4Ú�^8_����y�� ��'��t\^(�/}��n�/*�?Te� ���5D��T k��'�e��w�Q;Zc�w,����>��'2�A�k�ݿv��}��s��n�v��az� BW�A �"�im@�� �?Eք endstrea … ��EF��q�rf� CįQ9ZY�$r!���6m �)�4� ��V�9�k�J�$#�� Fь�X��٥�C��p�[��ģ)C���S�;rFP#�I�m�K�G ɺ��z���j>>��X�9,�ZL-j��Ib�k��ȉ8�˚?v�t���� �x������P�IO}�_ay@ ��:����|Ve�6�����ubd/e�3 T� Sؓ�7X����?MM�!���Լu�O��t����P Cbt;���i����ް��a��@gW��#�@��4c�9.D���o� z2>M�5��i�~�u0� �q�s �wQ�9�ǸLt��삟�Mz)>���kɝ���I�;���io�"���U)��]$Y���L >� $����$T����:gUo$���UK���,�C�`sCMAJMÄ��K��C(��g]���ٮ9�s�U�G�0?����L�5��� �QM%��0O�l��5&���`�Ƒ 1,��x�'���{��k+�mY�}��� … )��x) ���PEw>Q# �cƠ�;!�$a��� *��~;�E�+,�N ��%Ʋ�'���諪��Z-�9P�U9���c�Q��X�}�Rfp��b���) ��L}���-����9`OЕ,PTe���,�eo�#c�4$�IIϡ{bV�x� E6JA�%窮>���gbc����vb�:��� �n��2{8 �����Q��;��Nª�Q]�*=��} �Ũ"ӆ�ɯU{���?�j��RW��keOcz���)o��U�_|��N���Wo��W���?��������~����W_n�H!ڷ���i_,N ������o~s��˷�7�~�}���ӥ��=D�"�H�[,OpT�n`{�އV/� }����v������Z�������*�~�i��rrۿ�Rdiy�i�2/�n����� �����(Jf$oΨ��vz��q VE_�S�U�J� y���]!B�wp0O�3��~�i�=JDm%&T� ��屺�cB*$���Hx�v��۵Ӎ � (v�N9��
Ahren Leads Investment in Cell Mogrify - Ahren Innovation Capital We are now investing from our latest fund and have over $400M in dry powder Home Team Companies About News Connect Ahren Leads Investment in Cell Mogrify 29 October, 2018 LONDON & CAMBRIDGE, UK: Ahren announced today that it has closed an investment in a fourth portfolio company, Cell Mogrify. Cell Mogrify is a transformative cell therapy company at the intersection of computer science and molecular biology. The company has developed an algorithm to identify the transcription factors required to turn one cell type (for exam … biotechnology sector and in academia. About Ahren LP Ahren LP is an investment fund that supports transformational companies at the cutting edge of deep science and deep tech. The technologies of its Founding Partners are today valued in excess of $100BN combined. A group of highly diverse, creative and original thinkers leading their domains, Ahren believes in taking considered risk that will deliver superior rewards – capturing a generational opportunity to provide smart c … ory (Physics Department) of Cambridge University. Sir Venki Ramakrishnan, Nobel prize laureate and President of the Royal Society, the UK’s premier science body. Lord Martin Rees, world-renowned astrophysicist, Astronomer Royal, founder of CSER, former President of the Royal Society and former Master of Trinity College, Cambridge University. Sir Gregory Winter, inventor of technology leading to Humira ($18BN sales in 2017, the world’s greatest grossing drug) and founder of th … AIMER This press release does not constitute an offer of interests in any Ahren fund. Any offer of an Ahren fund will be made through separate offering documents and in accordance with applicable laws and regulations. This press release may contain forward looking statements. These statements include, but are not limited to, discussions related to Ahren’s expectations regarding the performance of its business, its liquidity and capital resources and the other statements … dication of the current or future performance of the portfolio companies of the fund that Ahren manages. Further Reading 24 September, 2024 News Constructive Bio Secures $58 Million in Series A Financing 17 April, 2024 News Mentee Robotics Unveils MenteeBot: a humanoid robot that integrates AI across all operational layers 3 August, 2023 News Adr
Big data-science for cell therapies: Mogrify boosted by $3.7m funding BioProcess International is part of the Informa Connect Division of Informa PLC Informa PLC | ABOUT US | INVESTOR RELATIONS | TALENT This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726. BPI Events About Subscribe Contribute Stay Updated Stay Updated Upstream Related Topics Bioreactors Biochemicals/Raw Materials Cell Culture Media Expression Platforms
Collaboration Deals in Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert Network FA … The Jackson Laboratory The Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center The Native Antigen Company The New York Stem Cell Foundation The Parker Institute For Cancer Immunotherapy Theragen Theragent TheraPanacea Theriva Biologics Thermo Fisher Scientific ThinkCyte ThirdEye Tianjin CanSino Biotechnology Tianjin University Tiba Biotech TiumBio Tivic Health Systems T Med TMG - Tropical Melhoramento e Genética Today TCI Tolo Biotech Tome … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … nology Related Reports Biotechnology Market Report by Product Type, Technology, Application, and Region 2026-2034  Report 138 Pages April 2026 Global From €3609 EUR $3,999 USD £3,129 GBP Biotechnology Market in the US 2025-2029  Report 170 Pages January 2025 United States From €2256 EUR $2,500 USD £1,956 GBP North America Biotechnology Market Report by Product Type, Technology, Application, Countries and Company Analysis 2025-2033  Report 200 Pages Sep … on Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
Asset->js('assets/js/cookie-banner', null, false) }}" as="script">--> --> Mogrify developing 'mind-blowing science' in the cell therapy space @ element('Front/sign_in_out_buttons') --> USA UK USA AU CA Watch --> My Proactive Feed Alerts Subscriptions Bookmarks Settings Sign In News Browse Latest news Live Market reports OTC Markets Small caps Coinsilium CEO and CFO discuss results, treasury strategy and accounting treatment - ICYMI 02:48 27 Jun --> Solvonis CEO on progress with potential alcohol use disorder treatment - ICYMI 01:43 27 Jun --> American Resources CEO provides update on
Mogrify completes Series A financing totaling $33 million USD | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for early-stage e … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources Mogrify completes Series A financing totaling $33 million USD Member news 4 May 2021 Mogrif … orm development and the exploration of cell reprogramming for novel therapeutic application. This second close of the Company’s Series A was led by Parkwalk Advisors and incorporates additional funding from strategic Corporate Pharma investor Astellas Venture Management as well as 24Haymarket, co-Founder of Abcam PLC, Dr Jonathan Milner, and Mogrify CEO, Dr Darrin M Disley OBE. Proceeds from the financing will be used to advance Mogrify’s immuno-oncology and ophth … ype to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to generate the scalable source of functional cell types required to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in immuno-oncology,
Thomas Graney - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Thomas Graney Board Member at Mogrify Limited Thomas Graney 's Executive Work History Current Board Member , Board Member Equilar on 03/11/2026 Mogrify Limited Past To view Thomas Graney's complete executive work history, sign up now Education B.S., University of Delaware M.B.A., New York University - Leonard N. Stern Scho
Mogrify strengthens team and relocates to the Bio-Innovation Centre, TusPark Cambridge - Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US Mogrify strength
Mogrify solidifies IP position surrounding core technology and expands platform algorithm to enhance cell conversion - Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREE … cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platform to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas. Uniquely positioned to address a … 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III. Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify Download PDF Mark Cavanagh 2022-05-09T10:42:22+00:00 Subscribe to our Newsletter OUR INVESTORS Newsletter Be the first to hear about our latest innovation, events and announcements by subscribing to our newsletter. Be the first to hear about our latest innovation, events and announcements by subscribing to our investors newslett
Collaboration Deals in Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert Network FA … The Jackson Laboratory The Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center The Native Antigen Company The New York Stem Cell Foundation The Parker Institute For Cancer Immunotherapy Theragen Theragent TheraPanacea Theriva Biologics Thermo Fisher Scientific ThinkCyte ThirdEye Tianjin CanSino Biotechnology Tianjin University Tiba Biotech TiumBio Tivic Health Systems T Med TMG - Tropical Melhoramento e Genética Today TCI Tolo Biotech Tome … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … nology Related Reports Biotechnology Market Report by Product Type, Technology, Application, and Region 2026-2034  Report 138 Pages April 2026 Global From €3609 EUR $3,999 USD £3,129 GBP Biotechnology Market in the US 2025-2029  Report 170 Pages January 2025 United States From €2256 EUR $2,500 USD £1,956 GBP North America Biotechnology Market Report by Product Type, Technology, Application, Countries and Company Analysis 2025-2033  Report 200 Pages Sep … on Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
Mogrify appoints Profs. Christine Mummery, Graziella Pellegrini and Giulio Cossu to Scientific Advisory Board - Cambridge Science Park Skip to content Discover Our Story Our Future Explore The Park Meet The Team Our Impact Available Space Park Life Life On The Park News & Updates What’s On Jobs Park Directory Visit Us Find Us Getting Here Get in Touch Jobs Directory Property Contact Jobs Directory Property Contact Discover Close Discover Open Discover Our Story Our Future Explore The Park Meet The Team Our Impact Available Space Park Life Close Park Life Open Park Life Life On The Park New … w members. Profs. Christine Mummery, Graziella Pellegrini and Giulio Cossu will apply their experience in the transition of stem cell approaches from proof-of-concept through the clinic to product approval, to support the Company in developing scalable off-the-shelf therapies for diseases with a high unmet clinical need. Profs. Mummery, Pellegrini and Cossu join Mogrify’s SAB, comprising academic and industrial leaders in drug discovery, immunology, oncology, bioinformatics,
Mogrify extends Series A financing to $46 million USD - Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US Mogrify extends Series A financing to $46 million … cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology … in M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management. Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify About Astellas Venture Management LLC Astellas Venture Management LLC (AVM) is the corporate venture capital organization dedicated to reinforcing Astellas Pharma Inc. (Astellas) to accomplish the strategic goals. The venture capital activity of AVM is designated since … . About Parkwalk http://parkwalkadvisors.com Parkwalk is the largest growth EIS fund manager, backing world-changing technologies emerging from the UK’s leading universities and research institutions. With £500m of assets under management, it has invested in over 160 companies across its Parkwalk Opportunities and Knowledge Intensive EIS Funds, as well as the award-winning enterprise and innovation funds Parkwalk manages for the Universities of Cambridge, Oxford, Bristol and
A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify® A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify ® Oncogene . 2022 Nov;41(48):5160-5175. doi: 10.1038/s41388-022-02505-5. Epub 2022 Oct 21. Authors Lin Ming Lee # 1 , Eleni G Christodoulou # 2 3 , Pavithra Shyamsunder 1 , Bei Jun Chen 2 3 , Kian Leong Lee 1 , Tsz Kan Fung 4 5 , Chi Wai Eric So 4 5 , Gee Chuan Wong 6 , En
The International Society for Stem Cell Research has honored its volunteer leaders with the 2025 ISSCR Public Service Award, including Mogrify Founder and computational biologist, Owen Rackham… | Mogrify LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in … l Research has honored its volunteer leaders with the 2025 ISSCR Public Service Award, including Mogrify Founder and computational biologist, Owen Rackham . ISSCR’s volunteer leaders honored with the 2025 ISSCR Public Service Award will be recognized at the ISSCR 2025 Annual Meeting in Hong Kong 11-14 June and their accomplishments noted throughout the year. Owen Rackham 1y I am excited to share that I have been recognized as a 2025 ISSCR Public Service Award Honoree! Read mo … en recognized as a 2025 ISSCR Public Service Award Honoree! Read more about the award and my fellow honorees. https://lnkd.in/eFf_dir7 20 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 9,231 followers View Profile Connect Explore content categories Career Productivity Finance Soft Skills & Emotional Intelligence Project Management Education Technology Leadership Ecommerce User Experience Recruitment & HR Customer Experience Real Estate M
Mogrify - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment … eries A Developer of autologous cell therapies $125M Khosla Ventures , Humboldt Fund & 7 others 65/100 9th Quell 2019 , London ( United Kingdom ) , Series B Developer of engineered regulatory T cell therapies for immune diseases $344M Syncona , Fidelity Investments & 17 others 65/100 10th Rezolute 2012 , Denver ( United States ) , Public Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI) - BVF Partners , Lincoln Park Capital &
Our Companies - Ahren Innovation We are now investing from our latest fund and have over $400M in dry powder Home Team Companies About News Connect Mogrify Aiming to transform cell therapy by the systematic discovery of novel cell conversions. About Mogrify has developed an algorithm to determine the transcription factors required to turn one cell type into another cell type without transition through a stem cell state. This is revolutionary. Direct conversion via an algorithmic method is swifter, more efficient and avoids the moral hazard of using stem cells. Mogrify was the brain child of Pr
Julian Gough wins Academic Entrepreneur of the Year award | MRC Laboratory of Molecular Biology Skip to content LMB Intranet Science Research Leaders Divisions Facilities Animal Research Training Seminars LMB Developed Software Published Research Careers & People Current Vacancies PhD Students Postdocs Group Leaders Technical & Operational Roles Student Placements Work Experience Employee Benefits LMB Life Equality, Diversity & Inclusion Alumni News & Events Latest News Seminars & Events Public Engagement LMB in the News Alumni News Achievements Awards & Prizes C … es About Leadership History Archive Contact Directory How to Find Us Max Perutz Fund Search LMB / News & Events / Julian Gough wins Academic Entrepreneur of the Year award Published 22/09/2020 Julian Gough wins Academic Entrepreneur of the Year award Julian Gough Julian Gough, a Group Leader in the Structural Studies Division, has been named the Cambridge Enterprise Academic Entrepreneur of the Year in the 2020 Business Weekly Awards. Julian has been recognised for his wo … a company that he co-founded while at the University of Bristol with the aim to apply his research on cell reprogramming to the development of cellular therapies. The Business Weekly Awards help to build a bridge between industry and academia, while celebrating science and technology companies and entrepreneurs in Cambridge and the East of England, with the Academic Entrepreneur of the Year award recognising outstanding work by an academic as an innovator, founder or consulta … these levels of understanding into development of innovative technologies. One application of this is in the field of regenerative medicine through prediction of factors that drive cellular reprogramming from one type of cell to another. The idea of cellular reprogramming is based on the observation that the variation in human cell appearance and function is derived from a complex regulatory network that modulates gene expression, such that introduction of certain transcript … ial future clinical benefit. Julian: “ I am both grateful and excited about the award. I feel so privileged that the fundamental science that I do at the LMB has a clear path to clinical translation. ” Further References Business Weekly Awards Mogrify Share this on Bluesky Other News LMB achieves Leaders in Openness status Lori Passmore elected a
Mogrify wins Life Science Innovation Award and Prof. Julian Gough named Academic Entrepreneur of the Year at Business Weekly Awards 2020 - Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEAT … EDIA FEATURES RESOURCES CAREERS CONTACT US Mogrify wins Life Science Innovation Award and Prof. Julian Gough named Academic Entrepreneur of the Year at Business Weekly Awards 2020 Mogrify wins Life Science Innovation Award and Prof. Julian Gough named Academic Entrepreneur of the Year at Business Weekly Awards 2020 PRESS RELEASE 18th September 2020 Download PDF Mogrify wins Life Science Innovation Award and Prof. Julian Gough named Academic Entrepreneur of the Year at Busines … hcare through direct cellular conversion technology Co-founder and CSO receives award celebrating his achievements in establishing Mogrify Cambridge, UK, 18 September 2020: Mogrify Limited (Mogrify ® ), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, today announced it had won the AstraZeneca Life Science Innovation category of the Business Weekly Awards. The award commends Mogrify in applyin … of Mogrify, received the Cambridge Enterprise Academic Entrepreneur of the Year award in recognition of his work as a life science innovator and founder of Mogrify. Mogrify’s proprietary direct cellular conversion technology determines the conversion factors required to convert ( ex vivo or in vivo ) any target cell type from any source cell type. The Company is deploying this platform to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety … a leading bioinformatician and biotech entrepreneur who led the development and application of the Mogrify platform, which utilizes a systematic big-data approach (Rackham et al ., Nature Genetics, 2016) developed over a 10-year period via a multi-national research collaboration. Graduating with a PhD in molecular biology from the University of C
Mogrify expands Scientific Advisory Board | Cambridge Network Skip to main content The Network Membership Who we are Make the most of our services Cambridge Cluster Cambridge NeuroWorks FAQ Companies Member directory News News listing Blog Events All events Cambridge Network events Advertise your event Boost your event Sponsorship Learning Training courses In-house courses Coaching services Graduate scheme Consultancy services Peer groups Learning FAQ Jobs Jobs listing Recruitment Packages Advertise your vacancies Connect with future talent Boost your job Tips for finding a job More Contact us … w members. Profs. Christine Mummery, Graziella Pellegrini and Giulio Cossu will apply their experience in the transition of stem cell approaches from proof-of-concept through the clinic to product approval, to support the Company in developing scalable off-the-shelf therapies for diseases with a high unmet clinical need. Profs. Mummery, Pellegrini and Cossu join Mogrify’s SAB, comprising academic and industrial leaders in drug discovery, immunology, oncology, bioinformatics, … pean Commission. Prof. Pellegrini is a recipient of the ISSCR and Louis-Jeantet Prize, and the Tissue Engineering and Regenerative Medicine International Society and European Tech Women Award, and has published over 100 peer-reviewed papers, book chapters and nine patents. She is also a founding member of the International Ocular Surface Society and is involved with numerous other societies, committees and meetings covering stem cells and regenerative medicine. Giulio Cossu, … d expertise alongside that of existing SAB members will be vital in driving the application of our direct cell conversion technologies to develop novel cell and gene therapies capable of progressing through clinical development and onto regulatory approval.” Christine Mummery, PhD, SAB Member, Mogrify, said: “Mogrify’s proprietary suite of platform technologies enable systematic identification of the key transcriptomic and epigenetic switches that drive the speed, efficiency
Founders | About us | Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US Our team Founders mogrifydigital 2026-02-25T12:34:27+00:00 Board of Directors Found … er of biotech companies. Prof. Owen Rackham Founder Owen is world expert in the application of machine learning and complex systems in cell reprogramming. He was a career development fellow at the Medical Research Council, UK and was the recipient of a Japan Society for Promotion of Science fellowship to work at the RIKEN Omics Science Centre in Yokohama. He is now an Assistant Professor at the Duke-NUS Medical School in Singapore. PROF. JOSE POLO Founder Jose has worked at t … w at the Harvard Stem Cell Institute. He was awarded a NHMRC career development fellowship, a Charles Viertel Senior Medical Research fellowship as well as an ARC future fellowship and is now a Professor at Monash University. Our Founders Subscribe to our Newsletter OUR INVESTORS Newsletter Be the first to hear about our latest innovation, events and announcements by subscribing to our newsletter. Be the first to hear about our latest innovation, events and announcements by s
Darrin M. Disley - Director & CEO at Mogrify | The Org Platform Enrich Pricing Log in Sign up Mogrify Darrin M. Disley Unverified Darrin M. Disley Director & CEO Contact Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown, or invested in over 40 start-up life science, technology and social enterprises, raising $600 million USD in business financing and closing $700 million USD in commercial deals. He was CEO of Horizon Discovery Group plc for 11 years, during which he led the Company from start-up through a $113 million USD IPO, … ene editing and gene modulation technologies. He was awarded a lifetime Queen’s Award for Enterprise Promotion in 2016 for his work in promoting enterprise across the UK and appointed OBE in 2018 for his services to business and enterprise in the healthcare sector. Org chart View org chart View position Joe Foster COO Alastair Kilgour Investment Director Julian Gough Chief Scientific Advisor SB Sarah B. Human Resources Manager Felipe Serrano Principal Scientist | Group Leader
Mogrify raises $3.7 million USD seed funding to accelerate its mission to transform cell therapy via direct cellular conversion - Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESO … ren Innovation Capital www.ahreninnovationcapital.com Ahren LP is an investment fund that supports transformational companies at the cutting edge of deep science and deep tech. The technologies of its Founding Partners are today valued more than $100 billion combined. A group of highly diverse, creative and original thinkers leading their domains, Ahren believes in taking considered risk that will deliver superior rewards – capturing a generational opportunity to provide smar … programs in the UK, via the Professor Christopher R Lowe Carpe Diem Enterprise Fund, and has backed over 40 start-up life science, technology and social enterprises. Darrin is an Enterprise Fellow at the Department of Chemical Engineering and Biotechnology, University of Cambridge, Honorary Fellow of the Cambridge Judge Business School and Honorary Visiting Fellow at the School of Environmental and Life Science at the University of Salford. He holds a BSc in Chemistry and a … niversity of Cambridge In 2016 Darrin was conferred with a lifetime-held Queens Award for Enterprise Promotion and in 2018 was appointed Officer of the Order of the British Empire by Queen Elizabeth II for his services to business and enterprise in the healthcare sector. About 24Haymarket www.24haymarket.com 24Haymarket is a premium deal-by-deal investment platform focused on high-growth businesses, investing up to £5 million in any company. 24Haymarket’s Investor Network inc
Board of Directors | About us | Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US Our team Board of Directors mogrifydigital 2026-03-11T09:57:40+00:00 Boar
Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor - Zyme Communications Skip to content Home About Us The Team News Events Careers Services Client Experience Case Studies Contact Us Search for: Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor Previous Next Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor Cambridge, UK, 02 November 2021: Mogrify Limited (Mogrify ® ), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming
Cellular Reprogramming | About us | Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US About Us About Us mogrifydigital 2026-02-25T13:04:45+00:00 Our Missio … cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across otology, ophthalmology, diabetes, and other disease areas with a high unmet clinical need. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commerciali … in M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund, as well as strategic investors; Astellas Venture Management. Explore our science Meet Our Leadership Team BOARD OF DIRECTORS FOUNDERS Our HISTORY 2009 FANTOM 5 LAUNCH RIKEN scientists launch an international consortium to provide insight into the regulatory landscape of the transcriptome across as many cell states as possible. • 2009 FANTOM 5 LAUNCH Lorem ipsum dolor sit amet, consectetur ad … eu. 2015 FOUNDATION PATENT Julian Gough, Owen Rackham, Jose Polo file a patent application for the V1 platform and over 30 direct cell conversions. • 2015 Foundation Patent Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolo … hree academic Co-founders: J. Gough, O. Rackham & J. Polo with pre-seed and grant funding to begin the industrial development and application of the V1 platform. • 2016 Incorporation Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
Industry News | One Nucleus Skip to main content Sign-up Log in Main navigation Events Events Overview ON Helix Genesis Annual Awards Industry Events One Nucleus Events Membership Membership Overview Member Benefits Membership Prices Member Directory Sponsorship Services Services Overview Savings Savings Overview Purchasing Scheme Event Savings Training Training Overview Upcoming Courses Training Sat Nav Mentoring Student & Post Doc Membership Facilities Management Facilities Management Overview Facilities Management Lab Space Equipment for Sale About Company Bio Our Team Our Board Publica … ies of carbohydrate-… Read more 22 November 2021 2021 Astellas Future Innovator Prize at We Are Pioneer Group Are you building an innovative and emerging life science or biotechstart-up?Now is your opportunity to accelerate your research and transform it into meaningful value for patients byapplying for an Astellas Future Innovator Prize.Astellas is o ering up to two Future Innovator Prizes for a pioneering science and technology platformthat would be a game-changing approach … Biology, Genetic Regulation, Immuno-Oncology, Cell Therapy, and other areas The award for each Astellas Future Innovator Prize winner will:Cover the… Read more 18 November 2021 PharmaVentures and Shinhan Investment Corp sign Memorandum of Understanding to strengthen global collaboration for the Korean biopharma industry OXFORD, England, Nov. 18, 2021 /PRNewswire/ -- PharmaVentures is delighted to announce it has signed a Memorandum of Understanding (MOU) with the leading Kore
Mogrify raises additional $16 million to advance its mission to transform the development of life-saving cell therapies - Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CA … nd was led by existing investor Ahren Innovation Capital (Ahren), an investment fund co-founded by leading UK scientific entrepreneurs, supporting transformational companies at the cutting edge of deep science and deep tech. Parkwalk, the largest EIS growth fund manager, backing businesses with IP-protected innovations creating solutions to real-world challenges, 24Haymarket, an early investor in Mogrify and a prolific early-stage investment syndicate in deep technology and t … deep technology and the life sciences, and the University of Bristol Enterprise Fund III, also contributed to the fundraise. Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state. The Company is deploying this platform to develop novel cell therapies addressing musculoskeletal, auto-immune, c … to secure this growth-funding without engaging in a protracted and distracting fund-raising process. Having now raised over $20 million, we can focus on delivery of our business strategy with the support of an aligned investor group. We will continue to engage with high-caliber investors with computational biology and cell therapy domain expertise as part of our on-going investor relations and capital markets strategy.” Alice Newcombe-Ellis, Founder and Managing Partner, Ahr … 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III. Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify About Ahren Innovation Capital www.ahreninnovationcapital.com Ahren LP is an investment fund that supports transformational companies at the cutting edge of deep science and deep tech. The technolog
Mogrify completes Series A financing totaling $33 million USD - Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US Mogrify completes Series A financing tota … latform development and exploration of cell reprogramming for novel therapeutic application Appointment of Dr Lorenz Mayr to the Board of Directors, as Non-Executive Director, and Dr Hiromichi Kimura, Astellas Venture Management, as an Observer Cambridge, UK, 04 May 2021: Mogrify Limited (Mogrify ® ), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, announced today the second … orm development and the exploration of cell reprogramming for novel therapeutic application. This second close of the Company’s Series A was led by Parkwalk Advisors and incorporates additional funding from strategic Corporate Pharma investor Astellas Venture Management as well as 24Haymarket, co-Founder of Abcam PLC, Dr Jonathan Milner, and Mogrify CEO, Dr Darrin M Disley OBE. Proceeds from the financing will be used to advance Mogrify’s immuno-oncology and ophthalmology pro … cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to generate the scalable source of functional cell types required to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in immuno-oncology, ophthalmology and other disease areas. Uniquely positioned to address a regenerative medicine market estimated to be worth $39 billi … n of novel cell-based and in vivo reprogramming therapies for broad therapeutic application. Based in Cambridge, UK, the Company has raised over $37 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic invest
Access Denied Access Denied You don't have permission to access "http://www.businesswire.com/AK_PM_VPATH1/714432/bw_maintenance.html" on this server. Reference #18.d0a0d517.1782539441.6b760c72 https://errors.edgesuite.net/18.d0a0d517.1782539441.6b760c72
Mogrify Appoints Jonathan Appleby as CSO | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Mogrify appoints Dr Jonathan Appleby as chief scientific officer - Samedan Advertise Contact Us Subscribe Follow Follow Home Publications European Biopharmaceutical Review European Pharmaceutical Contractor (EPC) Innovations in Pharmaceutical Technology (IPT) International Clinical Trials (ICT) Pharmaceutical Manufacturing and Packing Sourcer (PMPS) Pharmafocus Pharmafile Conferences News & Press Releases Directory Subscribe LnRiLWZpZWxke21hcmdpbi1ib3R0b206MC43NmVtfS50Yi1maWVsZC0tbGVmdHt0ZXh0LWFsaWduOmxlZnR9LnRiLWZpZWxkLS1jZW50ZXJ7dGV4dC1hbGlnbjpjZW50ZXJ9LnRiLWZpZWxkLS1yaWdodHt0ZXh0LWFsaW … Rare Diseases Unit, where he led the team that developed Strimvelis, the multi-award-winning and first autologous paediatric CD34+ stem cell gene therapy to be approved for commercial use. He also led for two years the ARSA gene therapy, which was later out-licensed to Orchard Therapeutics and recently approved as Lenmeldy. Dr Appleby previously held the position of director and portfolio manager at the GSK Centre of Excellence for External Drug Development, where he discove … cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across otology, ophthalmology, diabetes and other areas of disease with a high unmet medical need. Uniquely positioned to address a regenerative medicine market estimated to be worth £120bn ($150bn) by 2028, Mogrify is commerciali … arrin M Disley OBE, Dr Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management. Visit: www.mogrify.co.uk . Mogrify [email protected] 25 Cambridge Science Park Milton Rd, Milton, Cambridge CB4 0FW European Biopharmaceutical Review European Pharmaceutical Contractor Innovations in Pharmaceutical Technology International Clinical Trials Pharmaceutical Manufacturing and Packing Sourcer Pharmafile Pharm
Contact Us | Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US Contact Us Contact Us mogrifydigital 2026-03-04T12:19:00+00:00 [email protected] Bio-In … unt and to provide the products and services you requested from us. By clicking submit above, you consent to allow Mogrify Limited to store and process the personal information submitted to administer your request. For more information on our privacy practices, please review our privacy statement . Subscribe to our Newsletter OUR INVESTORS Newsletter Be the first to hear about our latest innovation, events and announcements by subscribing to our newsletter. Be the first to he
BioSpace Global Roundup, Sept. 24 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Release … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioSpace Global Roundup, Sept. 24 September 23, 2020 | 8 min read | Alex Keown Twitter LinkedIn Facebook Email Print Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. Mogrify – U.K.-based Mogrify Limited said it won the AstraZeneca Life Science In … AstraZeneca Life Science Innovation category of the Business Weekly Awards. The award commends Mogrify in applying its proprietary direct cellular conversion technology to further the cause of life science discovery for the benefit of human healthcare. Julian Gough, co-founder and chief scientific officer of Mogrify, received the Cambridge Enterprise Academic Entrepreneur of the Year award in recognition of his work as a life science innovator and founder of Mogrify. Immune R … cal, Inc., based in England, licensed the rights to Healthimation, LLC’s mobile application based digital program, a well-validated and award-winning 12-week program to help patients manage their weight and pre-diabetes or early diabetes conditions. The program is intended to be combined with the company’s proBEAT non-invasive patch CGM (continuous glucose monitor) for an enhanced behavioral change experience. Oxgene – Gene therapy company Oxgene, based in Oxford, England, an … n in the Evolve preservative free dry eye product line. Aequus has submitted an application for this new product with Health Canada for processing of a New Medical Device License. The new Evolve product added to the existing agreement is a unique preservative free formulation. The product formulation combines Hyaluronate and Carbomer 980 for the
Mogrify wins Innovation Award and Dr. Jane Osbourn, OBE receives Lifetime Achievement Award at Scrip Awards 2019 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Mogrify wins Innovation Award and Dr. Jane Osbourn, OBE receives Lifetime Achievement Award at Scrip Awards 2019 December 5, 2019 | 4 min read Twitter LinkedIn Facebook Email Print Mogrify platform recognized as having potential to transform future development of new medicines at prestigious awards ceremony Dec. 5, 2019 … ines at prestigious awards ceremony Mogrify Chair receives Lifetime Achievement Award for contributions to biologics discovery and development CAMBRIDGE, England--( BUSINESS WIRE )-- Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies, received MSD’s Innovation Award at the 15 th Annual Scrip Awards, and the Lifetime Achievement Award was presented to Dr. Jane Osbourn, OBE, Chair at Mogrify. The Innovation Award recognizes the significant … ure development of new medicines. Dr. Osbourn received the Lifetime Achievement Award in recognition of her outstanding contribution to the biotech industry throughout her career. Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform any human cell type into any other, without going through a pluripotent stem cell- or progenitor cell-state. The Company is using this platform to produce cell types with unrivaled safety, … deals, outsourcing and fundraising. This year’s new category, MSD’s Innovation Award, acknowledges and celebrates the outstanding scientific or technological breakthroughs that have the potential to be transformative in the discovery or development of new medicines. Scrip’s Lifetime Achievement Award is presented to individuals who have had a di
Mogrify Raises $3.7 Million USD Seed Funding to Accelerate Its Mission to Transform Cell Therapy via Direct Cellular Conversion - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals B … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Mogrify Raises $3.7 Million USD Seed Funding to Accelerate Its Mission to Transform Cell Therapy via Direct Cellular Conversion February 20, 2019 | 4 min read Twitter LinkedIn Facebook Email Print Promises to address the unmet market need for cell types that exhibit safety, efficacy and scalable manufacturing profiles s … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Mogrify adds Dr. Lorenz Mayr to Board of Directors and Scientific Advisory Board | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources Mogrify adds Dr. Lorenz Mayr to Board of Directors and Scientific Advisory Board Member new … another mature cell type. Mogrify is applying its proprietary and award-winning platform to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of cell therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas. Uniquely positioned to address a ce … 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III. Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify Return to listing Influencing policy Growing the sector Become a member Member benefits Join BIA News and insights Sign up to Newscast BIA Events Privacy Policy The Bi
Mogrify Introduces EpiMOGRIFY Platform to Systematically Identify Epigenetic Switches Driving Cell Identity and Cell Maintenance - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Mogrify Introduces EpiMOGRIFY Platform to Systematically Identify Epigenetic Switches Driving Cell Identity and Cell Maintenance October 9, 2020 | 3 min read Twitter LinkedIn Facebook Email Print Platform measures changes in H3K4me3 histone modifications to predict optimal growth factors required to both maintain cells … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Four New Biotechs to Watch: Esker, Mogrify, Isolere and BridGene - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Four New Biotechs to Watch: Esker, Mogrify, Isolere and BridGene May 5, 2021 | 4 min read | Mark Terry Twitter LinkedIn Facebook Email Print There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look. T … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Man … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss July 5, 2022 | 6 min read Twitter LinkedIn Facebook Email Print Mogrify Limited and Astellas Pharma Inc. announced that they have executed a collab … cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology … in M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management. Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify About Astellas www.astellas.com/en Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new dr … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Mogrify Extends Series A Financing to $46 Million USD - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases Al … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Mogrify Extends Series A Financing to $46 Million USD October 2, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced an additional $10 million USD closing of it … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Mogrify wins Business Weekly award for ‘Disruptive Technology’ - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Re … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Mogrify wins Business Weekly award for ‘Disruptive Technology’ March 21, 2019 | 3 min read Twitter LinkedIn Facebook Email Print Cell Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies, has won the ‘Disruptive Technology’ category at the Business Weekly Awards, in recognitio … ea. Professor Julian Gough, PhD, Co-founder and CSO, Mogrify, said: “This award is testament to the dedication of Mogrify’s multidisciplinary team who have invested their time and expertise in bioinformatics, cell reprograming and machine learning to deliver a direct cellular conversion platform, powered by next-generation sequencing and gene-regulatory data. Mogrify’s mission is to transform the future of cell therapy and it is an honor to have our disruptive technolog … nized at the Business Weekly Awards.” Business Weekly’s ‘Disruptive Technology’ Award is presented to the company in any sector whose science or technology is deemed to be genuinely game-changing. The award was presented to Mogrify at the annual dinner held at Queens’ College, Cambridge on Wednesday, 20 March 2019. Rackham OJL et al. A predictive computational framework for direct reprogramming between human cell types. Nature Genetics. 2016 Mar;48(3): … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min re
Mogrify Awarded $555,000 USD (£420,000 GBP) Innovate UK Funding to Accelerate Regenerative Cell Therapies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Mogrify Awarded $555,000 USD (£420,000 GBP) Innovate UK Funding to Accelerate Regenerative Cell Therapies March 18, 2019 | 2 min read Twitter LinkedIn Facebook Email Print Project to focus on data-driven cell conversions to produce cell therapies with potential application in wound healing, and oncology immunotherapy Ma … focus on data-driven cell conversions to produce cell therapies with potential application in wound healing, and oncology immunotherapy CAMBRIDGE, England--( BUSINESS WIRE )-- Cell Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies, today announced that it has been awarded $555,000 USD (£420,000 GBP) funding from Innovate UK, the UK’s innovation agency, through the investment accelerator for innovation in precision medicine. This … accelerator for innovation in precision medicine. This funding will support the application of Mogrify’s bioinformatic approach to transition three cell therapy products to preclinical stage, with potential application in wound healing, and oncology immunotherapy. Mogrify will utilize its patented systematic big-data approach (Rackham et al ., Nature Genetics, 2016) to identify, from next-generation sequencing and gene-regulatory networks, the sets of highly influential and n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Mogrify strengthens team and relocates to the Bio-Innovation Centre, TusPark Cambridge - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Mogrify strengthens team and relocates to the Bio-Innovation Centre, TusPark Cambridge May 20, 2019 | 5 min read Twitter LinkedIn Facebook Email Print Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies, today announced that it has moved to the Bio … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robot
Mogrify appoints Dr Jane Osbourn as Chair of the Board Home Categories Pharmaceutical Hi Tech Manufacturing Food Finance Company News Design & Build Containment Cleaning Sustainability HVAC Personal Protection Regulatory CT CONFERENCE Events Directory Search Close search Subscribe Login Password Password Remember me Forgot password? Close login form Cleanroom Technology Home Careers Mogrify appoints Dr Jane Osbourn as Chair of the Board Mogrify appoints Dr Jane Osbourn as Chair of the Board The OBE is also Chair of the Board of Directors of the BioIndustry Association, a Director of Babrah … ERIS wins Cleanroom Technology's Best Disinfectant Product (Spray or Wipe) Award The judge highlighted the product’s versatility and strong regulatory alignment, making it a reliable choice for global cleanroom operations Read more Design & Build Steriline to showcase pharmaceutical solutions at Pharma Pro&Pack Expo 2026 Visitors can meet the company's leadership team and discuss its latest pharmaceutical solutions and services at the Hyderabad exhibition. R
%PDF-1.3 %��������� 4 0 obj > stream xŝ[sǕ���)&/[Ԗc.�m�\�ٔ��$J�R�}�HPR�"����D�1���>��3�3 �TL�>�[��G����/�}��շ�d�쫯���y��!�G��/��f��uV���v���n��%�q�lׅ���o^�+W�ˏ��o�]���e��/*w��c]�E���b^�����7o�,��\g��]|��Y��.~�'^��ş��� ߬f �^�y �D�&�6��^����MQ���0�Z���d��Bp�o_dUv�s�� �������8džK�"�;7ܛ/ƩE���->�A��y�"�a�����=�~ acg��m&(W[�}'H�q2�;`��]wY� �˾�H6�SR��� �Zo�0 9(����xu��..Mo�l����v��U��N, ��mP�b.��^E� ���wJ ��1���^�[#��(�����6��iú��7��XS�|Y��%������6(��6��d��vq�"�-�;�@ ��l�8`9/� ����B�� �&����]J��u� Tof��X��Q�r#qB��� �5C�)$��4��K�M&�����n���g�xy�����O��~
Investors | Disruptive Biotech | Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US Investors Investors mogrifydigital 2026-03-04T11:42:20+00:00 Inve … tly inside the human body. The platform is protected by the foundational patent application and a suite of additional patent applications covering improvements and extensions to the core platform and specific cell conversions. Uniquely positioned to address a regenerative medicine market estimated to be worth £120 billion GBP ($150 billion USD) by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development par … stellas Venture Management . Ahren Innovation Capital Ahren LP is an investment fund that supports transformational companies at the cutting edge of deep science and deep tech. The technologies of its Founding Partners are today valued more than $100 billion combined. A group of highly diverse, creative and original thinkers leading their domains, Ahren believes in taking considered risk that will deliver superior rewards— capturing a generational opportunity to provide smart … END INVESTMENT GROUP Trend Investment Group is a Guernsey-based Venture Capital fund focused on the investment of biotech, healthcare, deep tech companies across the UK, Europe, and the US. We have a close collaborative and inclusive team of partners consisting of entrepreneurs, scientists, academic researchers, and financial experts with extensive investment experience from pre-series A to pre-IPO. Since establishment in 2016, Trend has invested in over 20 high potential and … ene editing and gene modulation technologies. He was awarded a lifetime Queen’s Award for Enterprise Promotion in 2016 for his work in promoting enterprise across the UK and appointed OBE in 2018 for his services to business and enterprise in the healthcare sector. DR. JONATHAN MILNER Jonathan, Founder of Abcam plc, is an experienced entrepreneur
Mogrify Ltd.. (11/2/21). "Press Release: Mogrify Appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor". Cambridge. - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant V … rapeutics Raises $5m Investment Led by Daphni Kos Biotechnology Partners: First Fund Reaches $123m Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events European Spatial Computing Healthcare Summit 2026 Leipzig EUROMAR … holm (NLSDays 2026) BIO-Europe 2026 Cologne (Köln) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
Mogrify adds Dr. Lorenz Mayr to Board of Directors and Scientific Advisory Board - Cambridge Science Park Skip to content Discover Our Story Our Future Explore The Park Meet The Team Our Impact Available Space Park Life Life On The Park News & Updates What’s On Jobs Park Directory Visit Us Find Us Getting Here Get in Touch Jobs Directory Property Contact Jobs Directory Property Contact Discover Close Discover Open Discover Our Story Our Future Explore The Park Meet The Team Our Impact Available Space Park Life Close Park Life Open Park Life Life On The Park News & Updates What's On Job
Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss - Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS M … cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology … in M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management. Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify About Astellas www.astellas.com/en Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new dr
Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor | One Nucleus Skip to main content Sign-up Log in Main navigation Events Events Overview ON Helix Genesis Annual Awards Industry Events One Nucleus Events Membership Membership Overview Member Benefits Membership Prices Member Directory Sponsorship Services Services Overview Savings Savings Overview Purchasing Scheme Event Savings Training Training Overview Upcoming Courses Training Sat Nav Mentoring Student & Post Doc Membership Facilities Management Facilities Management Overview Facilities Man
Dr Jonathan Appleby appointed by Mogrify as chief scientific officer Home Articles Magazines Log in Appointments Dr Jonathan Appleby appointed by Mogrify as chief scientific officer Mogrify has announced the appointment of Dr Jonathan Appleby as chief scientific officer. Dr Appleby, with his extensive experience, is set to spearhead the Company's therapeutic programmes, as a promising future for Mogrify awaits. Renowned scientist Dr Darrin M Disley OBE, CEO at Mogrify, reported: “We are thrilled to welcome Jon to the Mogrify Executive Team. Following a comprehensive global search that con
CEO resigns amid disposals at listed MedTech Business Cloud logo Choose Category Founders Naked Founder podcast Founder Friday Founder features Founder news News Insights Rankings/lists Northern Leaders 2025 Tech 50 innovation rankings Nominate for Tech 50s Events Newsletter Advertise About us Posted on March 10, 2025 by staff CEO resigns amid disposals at listed MedTech High-profile replacement announced by Roquefort Therapeutics as Ajan Reginald agrees to oversee trade sales of two subsidiaries Share: The CEO of Roquefort Therapeutics plc has resigned but will remain as a consultant to overs … f Cardiogeni Plc, a cardiac regenerative medicine company founded by 2007 Nobel Prize winner Sir Martin Evans. He led gene editing company Horizon Discovery from startup in 2007 to a £68m AIM IPO in 2014 and grew the business to generate significant revenues with a global presence before stepping down to pursue other interests in 2018. Horizon was eventually acquired by PerkinElmer in 2021 for a total Enterprise value of £296m. Disley has started, grown, or invested in over 4 … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Δ Already subscribed? News Insights Newsletter Events Contact us About us TechBlast Fire Up Co-Working Space, Old Fire Station Yard, Maclure Road, Rochdale OL11 1DN 0161 531 6630 [email protected] Content Appointments Deals Investment Sectors Cryptocurrency Cybersecurity EdTech EnviroTech FinTech HealthTech InsurTech LegalTech Manufacturing MarTech MediaTech MedTech PropTech Rec
Dr Jonathan Appleby appointed by Mogrify as chief scientific officer Home Articles Magazines Log in Appointments Dr Jonathan Appleby appointed by Mogrify as chief scientific officer Mogrify has announced the appointment of Dr Jonathan Appleby as chief scientific officer. Dr Appleby, with his extensive experience, is set to spearhead the Company's therapeutic programmes, as a promising future for Mogrify awaits. Renowned scientist Dr Darrin M Disley OBE, CEO at Mogrify, reported: “We are thrilled to welcome Jon to the Mogrify Executive Team. Following a comprehensive global search that con
A new technology for direct cell reprogramming - Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US A new technology for direct cell reprogramming Resources … The discovery of induced pluripotent stem (iPS) cells won Dr Yamanaka the Nobel Prize in Physiology or Medicine in 2012, which he shared with the UK cell biologist Sir John Gurdon. Since then, an increasing number of companies have been using iPS cells for disease modeling and drug screening and a few are developing medical therapeutics. A question now is whether the significant findings of Dr Yamanaka and colleagues can be taken to new levels by applying engineering principl … erapies 2021 | Joachim Luginbühl, Rodrigo Santos VIEW NOW Application Note Other Defining Cell Culture Conditions to Drive Cell Identity and Scalability in Cell Therapy 2021 | Aida Moreno-Moral, David Anderson VIEW NOW Commentary Other Cell Conversion Shortcuts Mapped with Predictive System 2016 | Julian Gough VIEW NOW Subscribe to our Newsletter OUR INVESTORS Newsletter Be the first to hear about our latest in
Jobs Companies Career Hub CV Analysis Industry Insights Career Guides Roles Library For employers Sign in Find my fit Jobs Companies Career Hub CV Analysis Industry Insights Career Guides Roles Library For employers Sign in Find my fit Mogrify Generated by Meeveem AI "Developing in vivo cell reprogramming therapies for degenerative diseases" Cambridge • 11 - 50 Employees • Biotechnology Claim this profile for free Connect About About Mogrify Mogrify develops treatments for degenerative diseases using proprietary cell reprogramming platforms. The company's MOGRIFY and epiMOGRIFY
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Cell Mogrify | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Cell Mogrify Website: Cell Mogrify Business Area(s) Cell and Gene Therapy DNA Sequencing Bioinformatics Description Mogrify has developed a systematic big data-science approach powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription
Modern Workplace Alliance | Mogrify Case Study | B2B Marketing Close Why Mogrify Mogrify Overview Meet our founders, hear why we're unique and see our core values. Customers Hear from our customers on how Mogrify helped them to achieved their goals. How We Work See what we do, how we do it and learn about our MAPR(TM) methodology. Request a Chat Contact Us How we help by team Sales Mogrify will partner with you to better integrate the sales & marketing functions in your business to build brand confidence, generate leads & push prospects into your sales funnel. Leadership Mogrify will r
Notice to Recruiters and Staffing Agencies - Mogrify Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US Notice to Recruiters and Staffing Agencies Notice to Recruit
Jane Osbourn joins Mogrify Board - European Biotechnology Magazine ADVERTISEMENT Stay up to date every week with the european biotechnology newsletter. ✕ Company This field is for validation purposes and should be left unchanged. Email (Required) This field is hidden when viewing the form EBcom NL confirm list This field is hidden when viewing the form Consent I agree to the privacy policy. Stay up to date every week with the european biotechnology newsletter. Log in here to read the desired article. Facebook This field is for validation purposes and should be left unchanged. Email (Req
Mogrify Teams Up With Sangamo To Streamline Cell Immunotherapy Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse
Mogrify: Decorated chair - European Biotechnology Magazine ADVERTISEMENT Stay up to date every week with the european biotechnology newsletter. ✕ Instagram This field is for validation purposes and should be left unchanged. Email (Required) This field is hidden when viewing the form EBcom NL confirm list This field is hidden when viewing the form Consent I agree to the privacy policy. Stay up to date every week with the european biotechnology newsletter. Log in here to read the desired article. Email This field is for validation purposes and should be left unchanged. Email (Required) Th … ds, Mogrify Chair Jane Osbourn has been presented with the Lifetime Achievement Award. She received the award in recognition of her outstanding contribution to the biotech industry throughout her career. ADVERTISEMENT Osbourn is a scientific leader in the field of antibody engineering with more than 30 years of experience in biologics discovery and development. She was Vice President for Research and Development and Site Leader at MedImmune (AstraZeneca), formerly Cambridge A … September. UK-based cell therapy developer Mogrify also received the Innovation Award at the same ceremony. © european biotechnology 9 December 2019 SHARE Share on Facebook Share on X Share on WhatsApp Share on LinkedIn Share by Mail YOU MIGHT ALSO LIKE clinical data ProQR validates RNA editing platform and raises $59.2m ProQR has reported the first clinical target-engagement data for its Axiomer RNA editing platform, while pricing a share offering and concurrent privat
Imagemagick mogrify geometry Jobs, Employment | Freelancer How It Works Browse Jobs Imagemagick mogrify geometry jobs Hire a Freelancer Earn Money Freelancing Freelancer Job Search imagemagick mogrify geometry 1 Search Keyword Where ? Search Filter My recent searches Filter by: Budget Fixed Price Projects to Hourly Projects to Duration All Durations Less than 1 week 1 week to 4 weeks 1 month to 3 months 3 months to 6 months Over 6 months / Ongoing Unspecified Contests to Type Local Jobs Featured Jobs Recruiter Jobs Full Time Jobs Skills enter skills Languages enter languages Job State All open … ills Languages enter languages Job State All open jobs All open and closed jobs Apply Filter Newest first Lowest budget first Highest budget first Lowest bids/entries Highest bids/entries 1,500 imagemagick mogrify geometry jobs found First 1 2 3 4 Next Last Corrupted MetaHuman Skeletal Mesh Extraction & Repair -- 2 6 days left Verified ...UE5’s native FBX exporter, the engine crashes with an error (“Array index out of bounds”), likely due to corrupted sk … choices are flexible; the design must hold up flawlessly in monochrome so I can apply colour later if needed. Acceptance criteria 1. All artwork delivered in AI, EPS, SVG a... Adobe Illustrator Branding Graphic Design Illustrator Logo Design Photoshop Vector Design Visual Design $98 Average bid $98 Avg Bid 167 bids Bid now UE5 MetaHuman Clothing Rigging Repair - Nylons & Stockings Weight Transfer 5 days left Verified ...corresponding Epic MetaHuman body templates (e.g., f … and the 52 ARKit facial blendshapes (which will be read as morph targets in our application). The Source File (.blend): The native Blender project file containing the raw, editable rig and weight painting data, ensuring we have a master copy for any futu... 3D Animation 3D Design 3D Modelling 3D Rigging Animation ARKit Blender Maya $42 Average bid $42 Avg Bid 19 bids Bid now Prototype Gear Assembly CAD Models 4 days left I need a clean 3 D solid model of a simple gear-and-sha … as soon as we start; you simply translate those specs into a watertight solid, apply sensible draft angles where needed, and double-check that the inner seal surface mates flush with the bottle rim. The project is finished once the STEP file opens error-free in SolidWorks or Fusion 360 and passes their default geometry integri... 3D CAD 3D Desig
Mogrify Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Mogrify Ltd. Startups | Holding Company | 2019 | United Kingdom | 50-100 | www.mogrify.co.uk Startups | Holding Company | 2019 | United Kingdom | 50-100 | www.mogrify.co.uk Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Congenital Disorders Eye Diseases Otorhinolaryngologic Diseases Cell therapy Disease domain score A glimpse into the focused therapeutic areas … itors worldwide and presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type, and Geography (North America, Europe, Asia/Pacific, and Rest of World). It also presents total market size figures with projected growth rates through 2030. Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identi … lobal Market for iPSCs by Technology 12.3 Global Market for iPSCs by Biomedical Application 12.4 Global Market for iPSCs by Derived Cell Type 12.5 Market Drivers 12.5.1 Current Drivers Impacting the iPSC Market Place 12.6 Market Restraints 13. COMPANY PROFILES For more information about this report visit https://www.researchandmarkets.com/r/pf57qx About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and ma … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Mogrify Jobs + Careers | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Mogrify Teams Mogrify Save Saved HQ Cambridge 54 Total Employees Year Founded: 2019 View Website Overview Jobs Offices Is This Your Company? Claim Profile Jobs at Mogrify Let Your Resume Do The Work Upload your resume to be matched with jobs you're a great fit for. Upload Resume Success! We'll use this to further personalize your experience. No jobs to discover at this time. back to overview Jobs at similar companies View All MassMu
Your marketing blueprint to attract acquisition or investors: 7 steps to successfully market your business for acquisition - Mogrify Close Why Mogrify Mogrify Overview Meet our founders, hear why we're unique and see our core values. Customers Hear from our customers on how Mogrify helped them to achieved their goals. How We Work See what we do, how we do it and learn about our MAPR(TM) methodology. Request a Chat Contact Us How we help by team Sales Mogrify will partner with you to better integrate the sales & marketing functions in your business to build brand confidence, generate leads
%PDF-1.4 %���� 11892 0 obj > endobj xref 11892 43 0000000016 00000 n 0000004770 00000 n 0000004937 00000 n 0000006847 00000 n 0000006963 00000 n 0000007495 00000 n 0000007623 00000 n 0000008199 00000 n 0000008693 00000 n 0000008962 00000 n 0000009281 00000 n 0000009650 00000 n 0000009961 00000 n 0000010678 00000 n 0000011367 00000 n 0000011498 00000 n 0000012316 00000 n 0000012747 00000 n 0000012799 00000 n 0000013955 00000 n 0000019962 00000 n 0000020019 00000 n 0000025901 00000 n 0000025981 00000 n 0000026292 00000 n 0000026649 00000 n 0000026767 00000 n 0000026847 00000 n 0000026884 00000 n … 6C39AF14385 xmp.did:767f52ae-1efe-47ff-a3ae-3058b7a0811d default converted from application/x-indesign to application/pdf Adobe InDesign CS6 (Windows) / 2021-03-29T08:42:18-07:00 application/pdf Adobe PDF Library 10.0.1 False endstream endobj 33 0 obj > endobj 34 0 obj >stream 2021-03-29T08:42:18-07:00 2021-03-29T08:42:20-07:00 2021-03-29T08:42:20-07:00 Adobe InDesign CS6 (Windows) uuid:2e6ddc33-6589-4472-b8ae-3472207c0ec7 xmp.did:767f52ae-1efe-47ff-a3ae-3058b7a0811d xmp.id:B … 6C39AF14385 xmp.did:767f52ae-1efe-47ff-a3ae-3058b7a0811d default converted from application/x-indesign to application/pdf Adobe InDesign CS6 (Windows) / 2021-03-29T08:42:18-07:00 application/pdf Adobe PDF Library 10.0.1 False endstream endobj 35 0 obj > endobj 36 0 obj > endobj 37 0 obj > endobj 38 0 obj > endobj 39 0 obj > endobj 40 0 obj > endobj 41 0 obj >stream SAMSUNG CAMERA PICTURES Copyright 2014 endstream endobj 42 0 obj >]/Filter[/DCTDecode]/Height 769/Length 647206/ … 97-c8531c0a20f0 xmp.did:8CAAAAA3162068118C14A4F4342F64E4 default converted from application/x-indesign to application/pdf Adobe InDesign 16.1 (Windows) / 2021-04-02T11:58:13-04:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 394 0 obj > endobj 395 0 obj >stream H��W�n�6}/����,�� ���d���H��奠$�&V�T���~}G��oi���L��Ι�=܄�U�b�j�U��p3�iRD,�����k D} �A�}:�ƅ`�;@F���y����_5�216�o`'tph�����m(�4|�����j�/�*C�\�׃�5(���A�����0�6Wtc���hI&LƂ���V�iTTj��5@��'D�p' … b52246537 xmp.did:e05ef738-8ad7-4fb3-baea-862ea3034cd8 proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign 16.1 (Macintosh) / 2021-03-19T08:08:10-05:00 saved xmp.iid:b804e8bb-bff3-d840-88d3-6f44652eeded 2021-03-30T12:06:29-07:00 Adobe Illustrator 25.0 (Windows) / saved xmp.iid:09a24805-5232-3a43-82be-a616013ad4e6 202
Mogrify–24Haymarket: investment, 202105 financing round Series A 2nd closing totalling $17m incl existing + co-investor 24Haymarket - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch … rapeutics Raises $5m Investment Led by Daphni Kos Biotechnology Partners: First Fund Reaches $123m Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events European Spatial Computing Healthcare Summit 2026 Leipzig EUROMAR … holm (NLSDays 2026) BIO-Europe 2026 Cologne (Köln) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
What's On at Biomarkers & Precision Medicine? Explore our brands Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. Events In-Person & Online Events Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities. Biomarkers, CDx & Precision Medicine US 2026 23 - 24 Sep 2026 | San Diego, CA Biomarkers, CDx & Precision Medicine 2026 1 … Research Director, Bioarchitech 180 papers. He was awarded the Leonidas Zervas Award of the European Peptide Society in 2012 and the Max Bergmann Medal by the Max-Bergmann-Kreis in 2022. His research covers topics at the interface between synthetic chemistry, biology, biophysics, medicinal chemistry, and nanobioscience. He currently serves as president of the European Peptide Society."> Knud Jørgen Jensen Professor, Copenhagen University Kuda Muchandibaya Lecturer for Supply … n academia and industry. He has won numerous awards, the latest being the Bader Prize by The Royal Society of Chemistry in 2023 and Fellow of the Royal Society of Edinburgh in 2024. Vendrell currently co-heads the IRR Chemistry Hub at the College of Medicine in Edinburgh as one of the first global hubs for collaborative non-siloed research to catalyse innovation in medical sciences and accelerate translational outputs. Group website: www.dynafluors.co.uk"> Marc Vendrell Escob … tise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com. Visit Website Cell Signalling Technology Bronze Sponsor Founded by research scientist … . United by a passion to make sense of complexities and overcome challenges, we apply our specialised knowledge to big-picture thinking. We will explore every option to deliver over and above for your project. We are thought leaders with a deep understanding of immunology, bioassays, molecular biology and a track record of groundbreaking discover
stem cells | Free Association Skip to primary content Skip to secondary content Free Association a blog from Nature Genetics Search Main menu Home Tag Archives: stem cells March issue cover: What’s going on here? Posted on 25 Mar 2016 by Brooke LaFlamme Reply Alamy photo “Talus cones on Svalbard” March is already winding to a close, but we wanted to take a quick break to answer that most burning of all questions: what is going on with our cover this month? On p.331 of this month’s issue , Owen Rackham and colleagues describe an algorithm called Mogrify that predicts tra … The epigentic landscape as imagined by Waddington involves a marble (the cell) rolling down a hill with many alternate paths (cell fates). You can imagine the image on the cover (depicting talus deposits on the surface of a mountain in Norway) as the epigenetic landscape, with the different cell fates rising out of the pluripotent state. In this case, there is no marble, because the cell and its fate (address on the landscape) are in fact the same thing. But similar to the t
Mogrify Raises $3.7mn Seed Funding to Accelerate its Mission to Transform Cell Therapy via Direct Cellular Conversion - Ahren Innovation Capital We are now investing from our latest fund and have over $400M in dry powder Home Team Companies About News Connect Mogrify Raises $3.7mn Seed Funding to Accelerate its Mission to Transform Cell Therapy via Direct Cellular Conversion 20 February, 2019 Darrin M Disley, PhD, DSc, OBE, appointed as CEO New investment from Ahren Innovation Capital, 24Haymarket and Dr Disley Mogrify’s technology enables the conversion of any mature cell type into any other … Haymarket and Dr Darrin M Disley, OBE. About Ahren LP Ahren LP is an investment fund that supports transformational companies at the cutting edge of deep science and deep tech. The technologies of its Founding Partners are today valued more than $100BN combined. A group of highly diverse, creative and original thinkers leading their domains, Ahren believes in taking considered risk that will deliver superior rewards – capturing a generational opportunity to provide smart capi … programs in the UK, via the Professor Christopher R Lowe Carpe Diem Enterprise Fund, and has backed over 40 start-up life science, technology and social enterprises. Darrin is an Enterprise Fellow at the Department of Chemical Engineering and Biotechnology, University of Cambridge, Honorary Fellow of the Cambridge Judge Business School and Honorary Visiting Fellow at the School of Environmental and Life Science at the University of Salford. He holds a BSc in Chemistry and a … iversity of Cambridge. In 2016 Darrin was conferred with a lifetime-held Queens Award for Enterprise Promotion and in 2018 was appointed Officer of the Order of the British Empire by Queen Elizabeth II for his services to business and enterprise in the healthcare sector. About 24Haymarket 24Haymarket is a premium deal-by-deal investment platform focused on high-growth businesses, investing up to £5MN in any company. 24Haymarket’s Investor Network includes several highly exper … AIMER This press release does not constitute an offer of interests in any Ahren fund. Any offer of an Ahren fund will be made through separate offering documents and in accordance with applicable laws and regulations. This press release may contain forward looking statements. These statements include, but are not limited to, discussions related t
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
%PDF-1.6 %���� 2 0 obj > endobj 5 0 obj > stream x��Xݎ�6����27��� �AF�aюT��,����M�N`^m/�H� u�0��j�D%�9��s��c��fY��+#�$ �߾�m �_� �w�)������ߧ���̼���p�����Ҽ �C�0�P����4�&��м�'�?'ƝT�p-lـ"�6 @9�m�H���w��Y �G���i���>� Lf�a{�m��%ə\�?��5or[I�1&��rd �_��#�ƀ �s���u�};��D��$ I:�4����= �|�Y�f�������=��Dp�QKQؕ���V �����ks��� �B���Kݹ�ý��PH��*�(�6�ޫ,؉]JO�%:�KԃგlN��VɃ>"��Ċ�U](Z����T�ش�c��|c� ��l3��c�,w��c%��ׅ�Br!��\H.$����`�w��04�M�xFf endstream endobj 19 0 obj > stream H�|W]o\5}��ه8 �1_��6m�[!U���v�T��9g�ݻA)���3����xz6O'�ά�������fo���a:y��ߟ��yvF�|?a� ����٦����
Cell therapy weekly: Acquisitions for Scientific Industries and BioLife Solutions - RegMedNet Skip to main content RegMedNet is part of Taylor & Francis Group. Taylor & Francis About us Our journals Our Digital Hubs Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK. Taylor & Francis Home Our journals Our journals Journal content Journal articles Follow us on social media Topics CAR-T Stem cells Cell therapy Gene … emoves clinical hold on gene therapy program for hemophilia B US FDA clears IND application for gene therapy candidate VY-HTT01 for Huntington’s disease UK’s first clinical trial-focused viral vector manufacturer announces official launch Top content eBook | Viral and non-viral gene delivery approaches Building a consortium to accelerate stem cell models for drug discovery Cell therapy weekly: nanoparticle platform for targeted gene therapy Related tags funding and financing
File: mogrify.html | Debian Sources DEBSOURCES Skip Quicknav Home Search Documentation Stats About sources / imagemagick / 8%3A7.1.2.24%2Bdfsg1-1 / www / mogrify.html File: mogrify.html package info (click to toggle) imagemagick 8%3A7.1.2.24%2Bdfsg1-1 view license information --> links: PTS , VCS area: main in suites: forky size: 78,744 kB sloc : ansic: 375,607; cpp: 22,680; xml: 11,581; sh: 6,685; perl: 6,285; makefile: 3,498; tcl: 459 file content (1515 lines) | stat: -rw-r--r-- 51,844 bytes parent folder | download | duplicates (2) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 … tag line" /> <!-- JSON-LD Structured Data --> <script type="application/ld+json"> { "@context": "https://schema.org", "@type": "SoftwareApplication", "name": "ImageMagick", "url": "../www/mogrify.html", "image": "../images/logo.png", "description": "ImageMagick is a powerful open-source software suite for creating, editing, converting, and manipulating images … nel">-channel <var>type</var></a></td> <td>apply option to select image channels</td> </tr> <tr> <td><a href="command-line-options.html#charcoal">-charcoal <var>radius</var></a></td> <td>simulate a charcoal drawing</td> </tr> <tr> <td><a href="command-line-options.html#chop">-chop <var>geometry</var></a></td> &l … #34;command-line-options.html#clut">-clut</a></td> <td>apply a color lookup table to the image</td> </tr> <tr> <td><a href="command-line-options.html#color-threshold">-color-threshold <var>start-color</var>-<var>stop-color</var></a></td> <td>force all pixels in the color range to white otherwise black</td> </tr> <tr> <td><a href="command-line … ;>-color-matrix <var>matrix</var></a></td> <td>apply color correction to the image.</td> </tr> <tr> <td><a href="command-line-options.html#colors">-colors <var>value</var></a></td> <td>preferred number of colors in the image</td> </tr>
%PDF-1.3 %���� 1 0 obj >]/PageLabels 7 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences >>> endobj 2 0 obj >stream 2020-06-09T14:13:05-05:00 2020-06-09T14:13:08-05:00 2020-06-09T14:13:08-05:00 Adobe InDesign 15.0 (Windows) uuid:9a6c08cf-c1a2-4e58-9d45-889512b69664 adobe:docid:indd:56aa14c2-c3f7-11d9-8173-9158ea34dc34 xmp.id:e2d75b3a-3e97-9b43-a212-f2b50b0f484a proof:pdf 1 xmp.iid:51286b2a-dbc9-3347-a459-256e081be2b1 xmp.did:03a2ff97-3900-a74a-91ce-6155195cfac0 adobe:docid:indd:56aa14c2-c3f7-11d9-8173-9158ea34dc34 default converted from application/x-indesign to application/pdf Adobe InDesign 15. … gn to application/pdf Adobe InDesign 15.0 (Windows) / 2020-06-09T14:13:05-05:00 application/pdf 18-5-SS-Mogrify.indd Adobe PDF Library 15.0 False PDF/X-1:2001 PDF/X-1:2001 PDF/X-1a:2001 endstream endobj 7 0 obj > endobj 3 0 obj > endobj 5 0 obj /LastModified /NumberofPages 1/OriginalDocumentID /PageUIDList >/PageWidthList >>>>>/Resources >/Font >/ProcSet[/PDF/Text/ImageC]/Properties >/XObject >>>/TrimBox[9.0 9.0 603.0 787.464]/Type/Page>> endobj 9 0 obj /LastModified /Numbero … ��ŗa�U�c�����ȮЀ���^ E����fE�'z.� > endobj 35 0 obj > endobj 43 0 obj >stream application/pdf 18-5-SS-Mogrify-F2new 2020-04-15T14:36:53-07:00 2020-04-15T14:36:53-07:00 2020-04-15T14:36:52-07:00 Adobe Illustrator 24.1 (Windows) uuid:d9ecb8df-a49f-4374-a1f7-e473ef653dc3 xmp.did:9f1c6cb7-6456-7444-8f0b-2cb3862d6164 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:ec932062-f425-c34f-ab61-0795eb4eb29d xmp.did:299fa997-dd13-2547-9165-51d4fef319f5 uuid:5D20892493BFDB11914A8 … 9f5 2020-04-07T11:02:29+01:00 Adobe Illustrator 24.1 (Windows) / converted from application/pdf to application/vnd.adobe.photoshop derived converted from application/vnd.adobe.photoshop to image/tiff saved xmp.iid:ec932062-f425-c34f-ab61-0795eb4eb29d 2020-04-07T15:29:42-07:00 Adobe Photoshop 21.1 (Windows) / saved xmp.iid:9f1c6cb7-6456-7444-8f0b-2cb3862d6164 2020-04-07T15:38:15-07:00 Adobe Illustrator 24.1 (Windows) / EmbedByReference C:\Users\ScottC\OneDrive - Informa plc\BP … :o ��g.~y�f�3e+ѓ��]�_!�� endstream endobj 25 0 obj > endobj 87 0 obj >stream application/pdf 18-5-SS-Mogrify-F1new 2020-04-07T15:34:55-07:00 2020-04-07T15:34:55-07:00 2020-04-07T15:34:54-07:00 Adobe Illustrator 24.1 (Windows) uuid:a8215201-b6e5-488f-b47e-9c5c0103a207 xmp.did:959a58b9-ba12-f441-9184-c26864db8999 uuid:5D20892493BFDB11914A8590D31
Partnering with Mogrify | Regenerative Medicine & Cellular Reprogramming Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US Partnerships Partnerships mogrifydig
Mogrify : Quotes, Address, Contact Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatolog … cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to engineer a renewable and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in immuno-oncology, ophthalmology and other disease areas. Uniquely positioned to address a regenerative med … 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III. Mogrify appoints Dr. Jonathan Appleby as Chief Scientific Officer Archived Mogrify News Mogrify extends Series A financing to $46 million USD Mogrify wins Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at CambridgeshireLive Business Excellence Awards 2020 Trending Stories Latest Interviews Top Life Sciences Articles Autism study reveals shared … nfidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel
In the Media | Mogrify | Reprogramming Health Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US Media Features Media Features mogrifydigital 2022-10-31T15:21:58+00 … th to Stem Cell Cures 27th November 2020 READ ARTICLE Mogrify scoops innovation award 22nd September 2020 READ ARTICLE Mogrify wins Innovation Award and Dr. Jane Osbourn, OBE receives Lifetime Achievement Award at Scrip Awards 2019 5th December 2019 READ ARTICLE UK biotech startup Mogrify injects $16M to get novel cell therapies to market soon 14th October 2019 READ ARTICLE Big data-science for cell therapies: Mogrify boosted by $3.7m funding 21st February 2019 READ ARTICLE S
techpartner.news Media Kit: Pipeline Open main menu Close main menu Brand Open the submenu Audience Editorial team Products Partner Content Open the submenu Articles Videos Partner Hubs Advertising Open the submenu eDM Newsletter Digital Displays Lead Generation Open the submenu Surveys Content Syndication Webinars Editorial Open the submenu Focal Point Podcasts Reports Events Open the submenu Benchmark Security Awards Kickstarter MSP Index Roadshow Channel Meets Golf Masters Pipeline Fast50 Roundtables Winter Ball Lists Contact Us Following the success of CRN Pipeline 2023, we are delighted t … rganisations and building Australia’s innovation economy for the future. Impact Award winners use technology to help their customers transform their businesses and demonstrate the highest levels of commitment to customer service and to delivering strong ROI. In 2023 Impact Awards celebrated the work of the partner community across three categories: projects , distribution , and innovation . • The projects category included: business transformation, workforce empowermen … ion 41 Hosting services 38 Telecommunications, internet and carrier services 37 Application/Software development 26 Analytics, business intelligence, big data 24 Mobility – mobile services and devices 24 Software for IT services 19 Data centre services incl power and cooling 15 Printing and managed print services 10 ERP/CRM software 10 Major Products and Services their company offers Product/Service Percent (%) Managed services 61 Back-up and disaster recovery 59 Public cloud … ion 41 Hosting services 38 Telecommunications, internet and carrier services 37 Application/Software development 26 Analytics, business intelligence, big data 24 Mobility – mobile services and devices 24 Software for IT services 19 Data centre services incl power and cooling 15 Printing and managed print services 10 ERP/CRM software 10 Agenda For a detailed version of the agenda please head to the Pipeline event page ! DAY 1: Tuesday 22 August Lunchtime Session Registration a
Cell Mogrify celebrates $3.7m seed close - Global Venturing Global Venturing | Cell Mogrify celebrates $3.7m seed close Where Global Innovation and Capital Meet Home --> Register Login Go Corporate University Impact Full Site Corporate University Impact Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors in … ons, closed its seed round at $3.7m today with investors led by patient capital fund Ahren Innovation Capital . The close followed an extension of undisclosed size and was backed by private equity firm 24Haymarket along with Cell Mogrify’s newly-appointed chief executive, Darrin Disley. Details of the initial seed tranche have not been disclosed, though the announcement confirmed Cell Mogrify would now seek series A funding. Mogrify has created a data analytics-driven cell co
Mogrify develops $16m series A - Global Venturing Global Venturing | Mogrify develops $16m series A Where Global Innovation and Capital Meet Home --> Register Login Go Corporate University Impact Full Site Corporate University Impact Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent c … universities, today raised a $16m first series A tranche led by patient capital fund Ahren Innovation Capital. Parkwalk Advisors, the fund management subsidiary of commercialisation firm IP Group, contributed to the round both directly and through its University of Bristol Enterprise Fund III. Private equity firm 24Haymarket also took part. Incorporated in 2016, Mogrify is working on direct cellular conversion technology that enables any mature human cell type to be transform … fy has now received $20m altogether, it said, though some of this appears to be grant funding. It previously obtained $3.7m in seed funding in February 2019 led by Ahren, with participation from 24Haymarket and chief executive Darrin Disley. Kilgour said: “We are delighted to be supporting the team at Mogrify, many of whom have been involved successfully with companies we have previously invested in, in this investment round. “The science and technology base Mogrify are build
Inner Ear Hair Cell Regeneration — Maybe We Can Know More | Page 161 | Tinnitus Talk Support Forum Search Everywhere Threads This forum This thread Search titles and first posts only Search titles only By: Search Advanced search… Everywhere Threads This forum This thread Search titles and first posts only Search titles only By: Search Advanced… Forums New posts Search forums Members Current visitors New profile posts Search profile posts Donate Log in Register Search Everywhere Threads This forum This thread Search titles and first posts only Search titles only By: Search Advanced search… Ever … into Dr. C. Liberman's research to restore hearing loss! Scientific Grand Prize awarded to renowned hearing loss researcher 1 1 1 2 CW Dragon Member Benefactor Sep 19, 2022 116 Midwest USA Tinnitus Since 07/2022 Cause of Tinnitus Impulse Noise Oct 26, 2022 #4,825 Oct 26, 2022 #4,825 Lins12 said: Maybe this will bring more funding and awareness into Dr. C. Liberman's research to restore hearing loss! Scientific Grand Prize awarded to renowned hearing loss res
Top newly founded UK university spinouts you should know about in 2021 - UKTN × Register for Free Bookmark your favorite posts, get daily updates, and enjoy an ad-reduced experience. Register Already have an account? Log in Skip to content Subscribe News Insights Insights Interviews Opinion Analysis Tech Hubs Tech Hubs London North East West Midlands Wales South East North West East Midlands Scotland South West East of England Yorkshire & Humber Northern Ireland Reports Podcast Events Jobs Login Log in Subscribe Login to remove this ad News Top newly founded UK university spinouts yo … the intellectual property created in the UK’s universities, they facilitate the application of new technologies in the world. UK is home to many well-known universities that have created industry leaders. It is one country that attracts aspiring individuals from all over the world with its chain of universities. As per the “Spotlight on spinouts: UK academic spinout trends” report , four of these universities – Oxford, Cambridge, Imperial College London, and … COVID. In April, Baseimmune raised £685K funding led by European university VC fund, Creator Fund along with participation from Mike Watson, ex-president of Moderna’s infectious disease spin-out with the support of Vaccitech and Oxford University. Maki VC and Rockmount Seed Investments also participated in this round. Baseimmune intends to use the funds to for the further development of its platform and also wants to start the pre-clinical development of vaccines in the lab. … ny bagged €7 million (nearly £6 million) Series A round from University Venture Fund, Oxford Sciences Innovation, and Parkwalk Advisors among others to develop its platform and find solutions to avert the global herbicide resistance crisis. Image credits: Mogrify Mogrify Founder/s: Prof. Julian Gough, Prof. Jose Polo, Prof. Owen Rackham Founded year: 2019 Funding: £16.2M Mogrify is a UK biotechnology company whose mission is to transform the development of ex vivo cell therap … tinue platform development and explore cell reprogramming for novel therapeutic application. Image credits: Cytoseek CytoSeek Founder/s: Professor Adam Perriman Founded year: 2017 Funding: £4.8M CytoSeek, a spinout from the University of Bristol, is on a mission to use Artificial Membrane Binding Protein technology to deliver the potential of the
#thebigexperiment #sciencecommunication #biotech | Mark Davison | 11 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agr … elping me bounce this idea around. -------------------------- I’m Mark Davison, award-winning CEO of Grant Instruments and host of “The Big Experiment” podcast. Follow me (and ring the 🔔) for posts about the people and business of science and technology. If you need laboratory equipment, we make some of the finest in the world. See www.grantinstruments.com or DM me if you want to talk specifics. #thebigexperiment #sciencecommunication #biotech …more 27 11 Comments Like Comme
Mogrify to accelerate novel IP and cell therapies using $3.7m USD funding Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastf … nfidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × Indiana University researchers investigate immune cell aging in Parkinson's disease
Sponsorship request: tsclient-0.56 Groups Groups Conversations All groups and messages Send feedback to Google Help Training Sign in Groups Groups linux.debian.devel Conversations About Privacy • Terms  Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable. Dismiss Learn more     Sponsorship request: tsclient-0.56 0 views Skip to first unread message  Andrew Lau unread, Dec 1, 2002, 1:50:05 PM 12/1/02   Delete You do not have permission to delete messages in this group Copy li
Direct Cellular Reprogramming | MOGRIFY® Technology Skip to content ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US ABOUT BOARD OF DIRECTORS FOUNDERS SCIENCE MOGRIFY® PLATFORM epiMOGRIFY® PLATFORM PIPELINE INVESTORS UPDATES NEWS MEDIA FEATURES RESOURCES CAREERS CONTACT US Science Mogrify mogrifydigital 2026-02-25T12:13:58+00:00 mogr … bsp; Evdokia Paza, Alice Lightowlers, Tim Landy, Geraint Parfitt VIEW NOW Application Note Metabolic Accelerating Regenerative Medicine Approaches to Type 1 Diabetes Through Direct Cell Reprogramming 2020 | Lawrence Billing VIEW NOW Application Note Other Computational Tools for Accelerating Regenerative Medicine 2020 | Aida Moreno-Moral VIEW NOW View all resources Subscribe to our Newsletter OUR INVESTORS Newsletter Be th
DDW Team, Author at Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Science … some people… Read More 22 September 2020 #News Mogrify scoops innovation award Mogrify has won the AstraZeneca Life Science Innovation category of the Business Weekly Awards. The award commends Mogrify in applying its proprietary direct cellular conversion technology to further the cause of life science discovery for the benefit of human healthcare. Prof. Julian Gough, Co-founder and CSO of Mogrify,… Read More 22 September 2020 #News #Narrated podcasts Optimisin
Instagram Instagram Log In Sign Up Close Never miss a post from cubiotech Sign up for Instagram to stay in the loop. Sign up Log in cubiotech • Follow More options cubiotech 239w Proudly introducing our Leaders in Biotechnology Series with an exciting line up of talks! 1. Charlotte Casebourne - CEO & Founder of Theolytics (8th November) 2. Dr Darrin Disley - CEO at Mogrify: Transforming Cell Therapy & Chairman at Celixir (29th November) 3. Dr John Maher - CEO of Leucid Bio (4th December) ...and many more to come, so keep your eyes peeled!! Load more comments No comments yet. Start the
Mogrify wins awards for innovation and named business of the year - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic A … er the field of in vivo reprogramming therapies, has been awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at the CambridgeshireLive Business Excellence Awards 2020. The awards acknowledge the potential of Mogrify’s proprietary suite of platform technologies that utilise a systematic big-data approach to direct cellular conversion and the maintenance of cell identity, to accelerate the development of regenerative cell and … offrin, CDO, Mogrify, said: “We are honoured to have been awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at the CambridgeshireLive Business Excellence Awards. We have an outstanding team of cellular reprogramming experts at Mogrify and this award is testament to their delivery of scientific, commercial and operational excellence.” Related articles Register now for DDW’s Cell & Gene Therapy Showcase 28 October